CEO Today Europe Awards

121 CEO TODAY EUROPE AWARDS 2020 Uni ted Kingdom Contact: Clinigen Group Plc Pitcairn House, Crown Square, First Ave, Burton-on-Trent, DE14 2WW T: +44 (0) 1283 495010 | w. www.clinigengroup.com Shaun is the Chief Executive Officer of the Clinigen Group plc and has the responsibility for the Group achieving its key performance indicators and plays a central role in setting the Group strategy. Shaun has played a pivotal role in the development of Clinigen, joining the company in January 2012 as Chief Operating Officer, when it was a privately owned company with a turnover of £82m. He was a key part of the executive team that took Clinigen through IPO in September 2012. Then as deputy CEO in 2015 and CEO fromNovember 2016, has been a fundamental part of the leadership of the impressive strategic growth of the company from £135m market capitalisation in 2012 to its current position as one of the largest companies on AIM on the London Stock Exchange. In 2017, Shaun oversaw the largest M&A healthcare deal of the year in the UK with the successful acquisition of Quantum Pharmaceutical plc, in addition to acquiring the largest supplier of unlicensed medicines in Japan, IMMC. Since, two further corporate acquisitions have been About Shaun Chilton made with CSM, a specialist provider of packaging, labelling, warehousing and distribution services, and iQone, a privately owned Swiss based speciality pharmaceutical business. Shaunwas awarded the Entrepreneur of the Year Healthcare (Western Europe) in 2017, 2018 and 2019 by the European CEO Awards. Prior to joining Clinigen, Shaun held senior global strategic, commercial and operational roles at Pfizer, Sanofi, Wolters Kluwer Health and the KnowledgePoint360 Group (now part of UDG Healthcare). Clinigen Group plc is a global pharmaceutical and services company with a unique combination of businesses focused on providing ethical access to medicines. Its mission is to deliver the right medicine to the right patient at the right time. The Group was formed in 2010 and joined AIM in 2012 and since has delivered strong shareholder returns with a more than six-fold uplift in market cap, which today is over £1bn, making it one of the biggest companies on AIM. The Group consists of three synergistic operations focused in three areas of global medicine supply; clinical trial, unlicensed and licensed medicines. Clinical Services Clinigen is the global market leader in the specialist supply, packaging, distribution and management of quality-assured comparator medicines and services to clinical trials and Investigator Initiated Trials. Unlicensed Medicines Clinigen is the global leader in ethically sourcing and supplying unlicensed medicines to hospital pharmacists and physicians for patients with a high unmet medical need. The Group manages early access programmes to innovative new medicines and provides ‘on- demand’ access globally to medicines Firm Profile which remain unlicensed at the point of care. Commercial Medicines Clinigen acquires global rights to niche hospital only and critical care products, revitalising these assets around the world and returning them back to sustained growth. It also provides access to licensed and branded generic medicines in the Africa and Asia Pacific region. The Group also has an ‘Unlicensed- to-Licensed’ (UL2L) strategy, where it looks to take unlicensed medicines with commercial potential and licences them, helping to address unmet medical need and allowing the Group to capitalise on its market- leading positions.